Literature DB >> 15608423

Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck.

Jun Wang1, Liqiang Xi, William Gooding, Tony E Godfrey, Robert L Ferris.   

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) metastasizes predictably to locoregional, cervical lymph nodes. Tumor cells can express various receptors that facilitate metastatic spread to lymph nodes and other nonlymphoid organs. Chemokine receptors (CCRs), normally expressed on lymphocytes, control immune and inflammatory cell migration, providing a link between innate and adaptive immunity. CCR expression was evaluated in HNSCC, and we showed a consistent pattern of CCR6 downregulation and upregulation of CCR7 in metastatic cells and tissues. Functional assays indicate that these surface receptors were functional on metastatic tumor cells. CCR6 downregulation is consistent with its decreased expression in cells emigrating from peripheral mucosal sites, while CCR7, important for homing of immune cells to secondary lymphoid organs, was significantly upregulated. Thus, CCR6, CCR7 and their ligands, normally important in controlling immune cell trafficking in response to inflammatory stimuli, may have an important role in determining the metastasis of HNSCC cells in vivo. Our data indicate that inhibition of CCR signaling may provide a targeted molecular therapy to prevent HNSCC metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15608423     DOI: 10.1159/000082501

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  15 in total

1.  Human β-defensin 3 promotes NF-κB-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck.

Authors:  Yvonne K Mburu; Koji Abe; Laura K Ferris; Saumendra N Sarkar; Robert L Ferris
Journal:  Carcinogenesis       Date:  2010-11-11       Impact factor: 4.944

2.  Expression of the chemokine receptor CCR6 correlates with a favorable prognosis in patients with adenocarcinoma of the lung.

Authors:  Yoshihiro Minamiya; Hajime Saito; Naoko Takahashi; Manabu Ito; Hiroshi Toda; Takashi Ono; Hayato Konno; Satoru Motoyama; Jun-Ichi Ogawa
Journal:  Tumour Biol       Date:  2010-09-25

Review 3.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

4.  PKCα take part in CCR7/NF-κB autocrine signaling loop in CCR7-positive squamous cell carcinoma of head and neck.

Authors:  Zhao Zhen-jin; Li Peng; Liu Fa-yu; Sun Liyan; Sun Chang-fu
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

Review 5.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

Review 6.  CCR7 mediates inflammation-associated tumor progression.

Authors:  Yvonne K Mburu; Jun Wang; Michelle A Wood; William H Walker; Robert L Ferris
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  Role of eotaxin-1 signaling in ovarian cancer.

Authors:  Vera Levina; Brian M Nolen; Adele M Marrangoni; Peng Cheng; Jeffrey R Marks; Miroslaw J Szczepanski; Marta E Szajnik; Elieser Gorelik; Anna E Lokshin
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

8.  [Constitutive expression of the potential stem cell marker CD44 in permanent HNSCC cell lines].

Authors:  R Pries; N Wittkopf; K Hasselbacher; B Wollenberg
Journal:  HNO       Date:  2008-04       Impact factor: 1.284

Review 9.  G-protein coupled chemoattractant receptors and cancer.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Nancy M Dunlop; Ji Ming Wang
Journal:  Front Biosci       Date:  2008-05-01

10.  Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases.

Authors:  Sen-sen Lin; Li Sun; Yan-kai Zhang; Ren-ping Zhao; Wen-lu Liang; Sheng-tao Yuan; Lu-yong Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-04-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.